Department of intervention, Tianjin Medical University Baodi Hospital, Tianjin, China.
Department of Cardiovascular Medicine, Tianjin Medical University Baodi Hospital, Tianjin, China.
PLoS One. 2024 Oct 16;19(10):e0311858. doi: 10.1371/journal.pone.0311858. eCollection 2024.
It remains unclear whether low-molecular-weight heparin (LMWH) is effective and safe for intracerebral hemorrhage (ICH) patients. This study presents a meta-analysis for elucidating effect of LMWH on preventing venous thromboembolism (VTE) among ICH patients.
Articles were located by systematically searching PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), WANFANG DATA, VIP, and SinoMed databases. The literature was independently screened by two authors, who also extracted data and conducted a qualitative evaluation. With regard to outcomes, their risk ratios (RRs) and 95% confidence intervals (CIs) were computed, and the findings were combined using the random effects model by using Mantel-Haenszel approach.
30 studies involving 2904 patients were analyzed and compared to control group. According to our findings, early low-dose LMWH, prophylaxis for VTE, was related to the markedly reduced deep vein thrombosis (DVT) (3.6% vs. 17.5%; RR, 0.25; 95% CI, 0.18-0.35; p-value<0.00001) and pulmonary embolism (PE) (0.4% vs. 3.2%; RR, 0.29; 95% CI, 0.14-0.57; p-value = 0.003), while the non-significantly increased hematoma progression (3.8% vs. 3.4%; RR, 1.06; 95% CI, 0.68-1.68; p-value = 0.79) and gastrointestinal bleeding (3.6% vs. 6.1%; RR, 0.63; 95% CI, 0.31-1.28; p-value = 0.20). Also, mortality (14.1% vs. 15.8%; RR, 0.90; 95% CI, 0.63-1.28; p-value = 0.55) did not show any significant difference in LMWH compared with control groups.
Our meta-analysis suggested that early low-dose of LMWH are safe and effective in ICH patients. More extensive, multicenter, high-quality randomized clinical trials (RCTs) should be conducted to validate the findings and inform clinical practice.
低分子肝素(LMWH)对脑出血(ICH)患者是否有效和安全尚不清楚。本研究进行了荟萃分析,以阐明 LMWH 预防 ICH 患者静脉血栓栓塞(VTE)的效果。
通过系统地搜索 PubMed、Embase、Web of Science、Cochrane 图书馆、中国知网(CNKI)、万方数据、维普和中国生物医学文献数据库(SinoMed)来定位文章。由两位作者独立筛选文献,并提取数据和进行定性评估。对于结局,使用 Mantel-Haenszel 方法通过随机效应模型计算其风险比(RR)和 95%置信区间(CI),并结合研究结果。
分析并比较了 30 项涉及 2904 名患者的研究,结果发现早期低剂量 LMWH 预防 VTE 与显著降低深静脉血栓形成(DVT)(3.6%比 17.5%;RR,0.25;95%CI,0.18-0.35;p<0.00001)和肺栓塞(PE)(0.4%比 3.2%;RR,0.29;95%CI,0.14-0.57;p=0.003)相关,而血肿进展(3.8%比 3.4%;RR,1.06;95%CI,0.68-1.68;p=0.79)和胃肠道出血(3.6%比 6.1%;RR,0.63;95%CI,0.31-1.28;p=0.20)无显著增加,且 LMWH 组与对照组的死亡率(14.1%比 15.8%;RR,0.90;95%CI,0.63-1.28;p=0.55)也无显著差异。
本荟萃分析表明,早期低剂量 LMWH 对 ICH 患者是安全且有效的。应开展更广泛、多中心、高质量的随机临床试验(RCT)来验证这些发现并为临床实践提供依据。